What should be checked before administering TCAs to patients?

Before administering tricyclic antidepressants (TCAs) to patients, it is essential to conduct a comprehensive metabolic panel (CMP) and a complete blood count (CBC). A CMP assesses various metabolic functions, including kidney and liver function, which is crucial since TCAs can affect these organs and may require dosage adjustments or increased monitoring for side effects.

The CBC can identify any pre-existing blood disorders, such as anemia or leukopenia, which might complicate treatment or increase risks of adverse effects. Monitoring these parameters helps ensure patient safety when initiating TCA therapy and allows for prompt detection of any potential complications that could arise during treatment.

While other tests, such as liver function and thyroid function tests, may also be relevant depending on individual patient factors, a comprehensive metabolic panel combined with a complete blood count provides a broad assessment of overall health that is particularly pertinent before starting TCAs.